Strategic partnership enables physicians to conduct clinical research and offer new clinical therapies to their patients
CHICAGO, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Allscripts (NASDAQ:MDRX) has partnered with Elligo Health Research to assist clinicians to conduct clinical trial studies in their own clinics. Through the Allscripts / Elligo partnership, clinical trials managed by Clinical Research Organizations (CROs) will be available, bringing new treatments to patients across major therapeutic areas.
The combined offering enables physicians to directly participate as study investigators in selected CRO clinical trials, and delivers the physicians’ patients the benefit of more direct comprehensive care. Additionally, physicians will be able to generate research revenue and cover investigator fees associated with trial procedures.
The Allscripts eParticipateSM service will be available to all Allscripts clients using the EHR platforms – Allscripts Professional EHR™, Allscripts TouchWorks® EHR and Allscripts Sunrise™.
CROs continue to increase investments to support bringing new clinical therapies to market, with more than $17 billion in payments to study investigators. eParticipate expands the reach of clinical trials investments by enabling Allscripts research-capable sites to become study investigators through Elligo’s infrastructure and services. Allscripts physicians will have access to clinical trials across several therapeutic areas, including Gastroenterology, Neurology, Pain, Urology, Pulmonology, Oncology and Women’s Health, some of the key areas of focus for CROs.
“By bringing clinical trials directly to their patients, physicians can remain focused on the direct care of patients while offering them new therapies,” said Allscripts Senior Vice President and General Manager of Payer and Life Sciences Jay Bhattacharyya. “Physicians will be able to participate in the benefits of clinical research without investing in expensive infrastructure.”
“Through our partnership with Allscripts, health care providers can identify patients for potential clinical research opportunities directly through their EHR,” said President of Elligo Health Research, Chad Moore. “Not only will patients gain access to treatments they might not have had otherwise, they will also participate from the comfort of their own physician’s office.”
Allscripts (NASDAQ:MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.
About Elligo Health Research
Elligo Health Research offers the only platform that brings clinical research to the clinic, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Elligo Goes Direct™ with an approach that uses electronic health records and other health data to identify real-world physicians and patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.
© 2017 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.
Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.
CONTACT: For more information contact: Allscripts Investors: Seth Frank 312-506-1213 firstname.lastname@example.org Allscripts Media: Concetta Rasiarmos 312-447-2466 email@example.com Elligo Media: Lea Studer 308-237-5567
News Provided by GlobeNewswire
© 2017 GlobeNewswire, Inc. All Rights Reserved